Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

Choroidal Neovascularization Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00370786
• Other study ID #: 8543
• Status: Completed
• Phase: Phase 3
• First received: August 30, 2006
• Last updated: July 9, 2008
• Start date: November 2005
• Est. completion date: February 2008

Study information

• Verified date: July 2008
• Source: hahid Beheshti University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iran: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: February 2008
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

Exclusion Criteria:

• Evidence of AMD

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Choroidal Neovascularization
• Neovascularization, Pathologic

Intervention

Drug:
• bevacizumab

Locations

Country	Name	City	State
Iran, Islamic Republic of	Hamid Ahmadieh, MD	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual acuity		6 months	Yes
Secondary	central macular thickness		6 months	No
Secondary	leakage in fluorescein angiography		6 months	No